Asia’s First Private Driving Club “THE MAGARIGAWA CLUB” Scheduled to Open Late 2022 in Tokyo Area
13.8.2020 13:00:00 EEST | Business Wire | Press release
Cornes & Company Ltd. started construction on THE MAGARIGAWA CLUB this past spring in Minamiboso in Chiba Prefecture. In creating the club, Cornes envisions a truly unique driving club, road course, and destination that will offer experiences unattainable at other racing circuits. Located 60minutes from the Tokyo metro area, Tokyo International Airport, and Narita International Airport, the exclusive driving club allows members to enjoy an unparalleled driving experience and spectacular views of Mt. Fuji and Tokyo Bay. In addition to its distinctive 3.5-kilometer driving course, THE MAGARIGAWA CLUB offers recreational options for everyone—not just car enthusiasts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200813005038/en/
Driving Course (Graphic: Business Wire)
The first round of applications for membership are sold out.
Concept
There are a few legendary racetracks in the world today. These spots gain iconic status, becoming destinations for piston-heads. Aiming to put THE MAGARIGAWA CLUB on the map, too, Cornes wants to turn it into an iconic destination by creating an exceptional, world-class driving club.
The name and logomark of the club are based on the kanji “<<<(magarigawa)”. Cornes hopes that MAGARIGAWA’s members will be able to fully immerse themselves in the beautiful natural landscape allowing them to become one with nature and have experiences that they won’t get anywhere else in the world.
Road course
The driving course was designed by the world renown team at Tilke Engineers & Architects. It is the first course in Japan that the team has designed from scratch and features a maximum ascent of 20%, maximum descent of 16%, and an 800-meter long straight, making it a track like no other. It is challenging but also designed for safety, letting drivers focus on the driving experience. Members can drive their automobiles on the course, store them on site, and get maintenance checks before and after driving. They can take one-on-one lessons with professional instructors and explore the potential of their favorite cars in a safe manner. The climate-controlled pit building can accommodate up to 36 vehicles and there are other services and facilities that help ensure a satisfying driving experience.
Other Major Facilities
Clubhouse
The design of the clubhouse combines elements from both traditional Japanese and contemporary architecture. Inside the clubhouse members will find a bar, restaurant, family lounge, gymnasium, 25m swimming pool, spa facilities, and natural hot spring baths. Outside, there is a playground, dog run, and hiking trails.
Owner’s paddocks and long-term garage
Each owner’s paddock provides private indoor parking for up to 4 automobiles and features a spacious floorplan that includes a dining area, living room, and terrace. There is also a long-term car storage facility which is highly secure and climate controlled. On-site mechanics keep members’ vehicles in top condition for driving.
“Magarigawa will be home for car lovers. A sanctuary where members will be able to enjoy and share their passion with friends and family.” said Kenzo Watari, CEO, Cornes Group.
“It will be the answer to the perennial question – where do you drive an 800 horsepower supercar?”
“The extremely hilly topography offers an astonishing basis for the track and makes the layout absolutely unique in the world.” said Dr. Carsten Tilke, Managing Director, Tilke Engineers & Architects. “Although we have designed and realized over 80 racetracks worldwide including 19 Formula One circuits, this project was very special to us and we are proud to be part of it.
Drivers will enjoy mid-speed, technical sections as well as two high-speed straights of the 3.5km track, which incorporates highest safety and environmental standards. It will be ideal for all kinds of driver skills. As a car enthusiast and racing driver myself, I can’t wait to drive my first laps at this amazing unique track.”
For more information, visit www.magarigawa.com.
Overview
Name: THE MAGARIGAWA CLUB
Location: Minamiboso, Chiba Prefecture, Japan
Date of opening: Scheduled for late 2022
Total site area: 1,000,000sq.m
Track specs: 3.5km in length, max. ascent: 20%, max. descent: 16％, 800m long straight, 22 corners, elevation change of 250m
Convenient: 60minutes from Tokyo & Haneda Airport
About Cornes & Company Ltd.
Established in 1861, Cornes & Co., Ltd. specializes in the import and sale of electronic components, systems equipment, industrial machinery, laboratory equipment and scientific instruments, apparels, fragrances, kitchenware, and nautical charts and publications and has expanded its business into a wide range of areas including non-life insurance and marine insurance survey. Its subsidiary companies Cornes Motors Ltd. and C.P.S. Ltd, are authorized distributors of Rolls-Royce, Bentley, Ferrari, Lamborghini, and Porsche automobiles. Cornes Motors is the leading ultra luxury automotive dealership in Japan.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200813005038/en/
Contact information
Contact for inquiries regarding this matter
Platinum Co., Ltd.
Person in charge: Saori Miyazaki
Email: magarigawa_pr@vectorinc.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom